All In Biotech

Free tool

FAERS Monitor: Xigduo Xr

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 205649 or its brand name (Xigduo Xr, Dapagliflozin, Metformin Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

3,503

Serious

2,578

74% of reports

Hospitalization

1,171

Death reported

227

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • nausea233
  • blood glucose increased232
  • diarrhoea179
  • vomiting179
  • weight decreased178
  • diabetic ketoacidosis177
  • off label use176
  • fatigue146
  • drug ineffective133
  • death129
  • dizziness110
  • acute kidney injury109
  • asthenia101
  • ketoacidosis98
  • headache89

Reports by year received

View as table
YearReports
20141
2015156
2016239
2017239
2018241
2019374
2020329
2021311
2022285
2023343
2024397
2025317
2026271

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,656 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
ketoacidosisSignal9879.765.47,437
diabetic ketoacidosisSignal17744.638.67,448
blood glucose increasedSignal2327.46.51,288
acute kidney injurySignal1094.33.6272
weight decreasedSignal1783.83.3374
vomitingSignal1792.32.0131
nausea2331.81.680
diarrhoea1791.71.448
asthenia1011.61.323
dizziness1101.31.19
off label use1761.21.06
fatigue1461.11.02
death1290.90.81
headache890.90.72
drug ineffective1330.60.536

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.